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SUMMARY
Anaphylaxis is a rare condition in pregnancy. Drugs are
the aetiological agents most often implicated. Maternal
anaphylaxis can lead to signiﬁcant fetal morbidity and
even mortality if uterine perfusion and maternal
oxygenation are compromised. Signiﬁcant risk of
neonatal neurological damage or death can occur even
when the maternal clinical outcome is favourable. The
authors present the case of a newborn, born at
gestational age of 29 weeks, who died at 11 days of life
with hypoxic–ischaemic cerebral injuries as a
consequence of maternal anaphylaxis following the
administration of amoxicillin in the community setting.
BACKGROUND
Anaphylaxis in pregnancy is considered a rare con-
dition with an estimated prevalence of 2.7 cases/
1 00 000 deliveries.1 Antibiotics are the most
common trigger.2–5 There is no evidence that
anaphylaxis occurs in the fetus but maternal
anaphylaxis can lead to signiﬁcant fetal morbidity
and mortality if uterine perfusion and maternal
oxygenation are compromised.6 There is a signiﬁ-
cant risk of fetal/neonatal neurological damage or
death even when the maternal outcome is favour-
able.6 All previous reports of maternal anaphylaxis
occurred in a hospital setting.2–5 7–18 The authors
report a case of maternal anaphylaxis in a commu-
nity setting. In the era of chemoprophylaxis of
Group B streptococcal (GBS) infections, accurate
identiﬁcation among predisposed pregnant women
is mandatory.
CASE PRESENTATION
The authors report the case of a neonate, ﬁrst
daughter of unrelated parents. The mother was
aged 21 years (gravida 1, para 1) with a medical
history of asthma but without previous episodes of
anaphylaxis or drug allergies. She reported that she
had been treated with amoxicillin earlier without
any symptoms. The pregnancy had been uneventful
with ﬁrst and second trimester serology and the
fetal sonograms were reported as normal.
Forty-eight hours before labour, the mother, at a
gestational age of 28 weeks and 5 days, was admitted
to another hospital’s emergency service complaining
of itching rash, oedema of the lips, vomiting and diz-
ziness. She was under treatment with amoxicillin for
an acute otitis media and reported the symptoms
started soon after the second dose. Fluids, steroids
and antihistamines were promptly administered par-
enterally. The obstetric evaluation was unremarkable
with infection screening negative and fetal
sonographic examination reported as normal. Owing
to uterine contractility on cardiotocography (CTG)
she was also medicated with indomethacin, magne-
sium and erythromycin. Hospital discharge took
place a few hours later.
In the next 24 h the mother was admitted to
another emergency service with a complaint of
decreased fetal movements. Obstetric evaluation
showed an immobile fetus, fetal tachycardia (170–
180 bpm) with absence of variability. Based on
these clinical ﬁndings the mother was transferred to
our maternity hospital.
On admission, the mother’s vital signs were
normal and general physical examination was unre-
markable. A single intrauterine pregnancy with intact
membranes was conﬁrmed. Maternal infection
screening was negative. Maternal serum β-tryptase
and urinary N-methylhystamine (NMH) were
unavailable. Ultrasound examination conﬁrmed an
immobile fetus and the Doppler study revealed a
high resistance in middle cerebral (1.9) and umbilical
arteries (3.5). No more antenatal corticosteroids had
been administered. An emergency caesarean section
was performed. At birth the female newborn was
pale, hypotonic and bradycardic, without spontan-
eous breathing or reﬂexes. The APGAR scores were 1
6 and 6 at the 1st, 5th and 10th min, respectively.
The newborn was intubated, resuscitated and trans-
ferred to the intensive care nursery for further care.
The birth weight was 1350 g (50th percentile). The
blood gases showed metabolic acidosis (pH 7.18;
BE: −7 mEq/l) which was quickly buffered.
OUTCOME AND FOLLOW-UP
The mother’s hospital course was uneventful and
she was discharged home 4 days later. The baby,
however, was not so fortunate. From day 1 of life she
remained mechanically ventilated. Echocardiography
showed global contractile dysfunction, without struc-
tural heart disease, stabilised with inotropic drugs.
Chest radiograph showed grade III hyaline membrane
disease. Infection and metabolic screens were nega-
tive along with blood cultures obtained following
admission to the neonatal intensive care unit and
maternal serologic studies (parvovirus, enterovirus
and TORCH). She received empirical ampicillin and
gentamicin, exogenous surfactant and standard care
for the gestational age. Nevertheless, the neonate’s
neurological status remained severely compromised,
without an obvious cause related to prematurity. She
maintained an abnormal state of consciousness
(comatose), hypotonic, without spontaneous move-
ments, ﬁxed mydriasis and absence of reﬂexes.
Cranial ultrasonography from the ﬁrst days (ﬁgure 1)
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and MRI (ﬁgure 2) at 10 days of age exhibited changes consistent
with hypoxic–ischaemic cerebral lesions. On the 11th day of life
the neonate died.
INVESTIGATIONS
The mother was evaluated by an allergist. Positive skin test
results and serum-speciﬁc IgE levels testing to ascertain the
causative agent were undertaken and conﬁrmed sensitisation to
amoxicillin. She started a desensitisation therapy.
Morphological examination of the placenta showed normal
maturation with severe vasoconstriction of umbilical arteries
(ﬁgure 3). Placental mast cells colouration was negative suggest-
ing previous degranulation of mast cells (ﬁgure 4).
Neonatal autopsy was performed. The brain external examin-
ation was unremarkable. The internal examination revealed
brain hypoxic–ischaemic lesions with diffuse subcortical leuko-
malacia (ﬁgure 5), thalami infarction (ﬁgure 6), white matter
lesions with microvacuolation and gliosis in the frontal lobe and
selective neuronal ischaemic degenerescence of brain stem,
thalami and basal ganglia (ﬁgure 7) with reactive astrocytes. The
histology of all other organs was unremarkable.
DISCUSSION
This case represents a life-threatening complication to both
mother and her fetus following the standard practice of mater-
nal infection treatment in an ambulatory setting.
Anaphylaxis is currently deﬁned as a serious allergic reaction
that is rapid in onset and might cause death.19 The lifetime
prevalence of anaphylaxis in the general population is estimated
at 0.05–2%.19–24 Data regarding prevalence among pregnant
women is limited1 6 with an estimated prevalence near or at the
time of delivery reported as 2.7 cases of anaphylaxis per
100 000 deliveries.1 Anaphylaxis in pregnancy places both
mother and fetus at an increased risk of fatality or fetal hypoxic/
ischaemic encephalopathy.25 Any agent that can trigger anaphyl-
axis in a non-pregnant state can potentially trigger it in suscep-
tible pregnant women.6 26 During the ﬁrst, second and third
trimesters, potential triggers are similar to those in non-
pregnant women. During labour and delivery, anaphylaxis is
usually triggered by iatrogenic interventions such as oxytocin,
or more commonly, an antimicrobial source such as penicillin or
cephalosporin administered to the mother for prophylaxis of
neonatal group B haemolytic streptococcal (GBS) infection.25
Although pregnant women are exposed to antibiotics in the
community setting, all previously reported cases of antibiotic
anaphylaxis during pregnancy have occurred in hospitalised
Figure 1 Cranial ultrasound. Coronal
planes (A) and sagittal planes (B and
C): symmetric, diffuse periventricular
white matter echogenicity (A),
hyperechoic aspect of cerebellum,
thalami and basal ganglia (B and C).
Figure 2 MRI performed at 10 days
of life: axial T1-weighted MRI showing
frontoparietal, pericentral and temporal
necrosis. Hypersignal of thalami and
lentiform nuclei. Cavitation necrosis in
brain stem—lesions compatible with
diffuse hypoxic encephalomalacia.
Figure 3 Umbilical cord pathology. Presence of three umbilical
vessels with severe vasoconstriction of umbilical arteries (arrow).
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women (table 1) even though this may represent publication
bias.2–4 7–18 The cases have been reported in association with
surgical prophylaxis prior to caesarean delivery, during prophy-
laxis of neonatal GBS infection or during treatment of maternal
pyrexia. The authors report the ﬁrst case of drug-induced mater-
nal anaphylaxis in a community setting.
The diagnosis of anaphylaxis during pregnancy is similar to
non-pregnant patients and is based on a meticulous history and
physical examination.6 26 It relies primarily on clinical criteria
and is valid even if the results of laboratory tests are within
normal limits, such as serum β-tryptase levels.6 26 Positive skin
test results or increased serum speciﬁc IgE levels to potential
triggering allergens conﬁrm sensitisation but do not conﬁrm the
diagnosis of anaphylaxis because asymptomatic sensitisation is
common in the general population.21 Clinical criteria have been
deﬁned and can be applied to pregnant women.6 19 26 It is con-
sidered to be highly likely when any one of three clinical criteria
are fulﬁlled (box 1). The presence of reduced blood pressure or
shock is not necessarily required. The terms anaphylactoid or
pseudoanaphylaxis are no longer recommended for use.21 The
mother of this neonate fulﬁlled the clinical criteria of
anaphylaxis.
Maternal anaphylaxis constitutes a major concern for obstetri-
cians and neonatologists. An alteration in immunological status
due to increased progesterone level during pregnancy may pre-
dispose pregnant women to anaphylaxis even though the high
levels of placental histaminase may act as a protective mechan-
ism for the fetus.2 27 28
In the presented case, the mother had previously received
penicillin-based antibiotics without any allergic reactions, sug-
gesting that immunological changes in pregnancy may have trig-
gered new-onset sensitisation. There is no solid evidence that
anaphylaxis occurs in the fetus because speciﬁc maternal IgE
antibodies are not transmitted across the placenta.29–32 The
developing fetal central nervous system is often more affected.2
In the presented case, as reported in the literature, maternal
hipovolemia, hypoxia, uterine hypoperfusion, umbilical vessels
vasoconstriction and peripheral fetal vasodilation induced by
histamine could lead to the impairment of fetal regulation of
cerebral ﬂow and induced severe neurological damage.6 26 As
discussed in previous reports, the magnitude and duration of
maternal hypotension probably determine the extent of injury
while fetal maturity possibly dictates the site of injury.2 13 The
primary sites affected in full term neonates are often the basal
Figure 4 Placenta pathology.
Placenta normal maturation.
Mastocytes colouration was negative.
Figure 5 Newborn autopsy. Coronal plane of brain with the presence
of subcortical leukomalacia (arrow). Figure 6 Newborn autopsy. Thalami with an infarct lesion.
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ganglia and thalamus. In contrast, in preterms, severe hypoten-
sion results in infarction of the deep grey matter, brainstem and
cerebellum.2 13 33 Another issue that inﬂuences the management
and outcome is the biphasic reaction of anaphylaxis that may
occur in up to 20% of patients in the ﬁrst 72 h.6 For this
reason, continuous fetal monitoring for 24–72 h after maternal
anaphylaxis is crucial in order to identify precocious signs of
fetal distress.
Increased umbilical and cerebral arteries resistance index (RI)
is another indicator of poor outcome. Sustained asphyxia with
subsequent development of haemorrhaging or diffuse cerebral
oedema, induce a loss of forward diastolic ﬂow resulting in
increased RI.33 The presence of gliosis and selective neuronal
necrosis described in the pathological neonatal examination esti-
mate the date of injury (10–15 days after hypoxic injury). The
neonate died on the 11th day of life and the sentinel event took
Table 1 Summary of case reports involving drug-induced anaphylaxis during pregnancy in the last 20 years
Author (year) Agent
Gestational age
(weeks) at onset Setting
Maternal clinical
presentation Maternal outcome Neonatal outcome
Heim et al (1991)7 Ampicillin 36 Hospital Hypotension Good Neurological damage
Edmonson et al (1994)8 Suxamethonium 36 Hospital Hypotension Good Neurological damage
Suri et al (1999)9 Suxamethonium 23 Hospital Hypotension Good Neurological damage
Konno et al (1995)11 Cefazolin 36 Hospital Hypotension Good Good
Luciano et al (1997)10 Iron 27 Hospital Hypotension Good Neurological damage
Dunn et al (1999)12 Penicillin 35 Hospital Hypotension Good Good
Gei et al (2003)5 Ampicillin 40 Hospital Hypotension Good Good
Berardi et al (2004)13 Ampicillin 37 Hospital Hypotension Good Neurological damage
Jao et al (2006)14 Cefazolin 37 Hospital Hypotension Good Good
Sheikh et al (2007)15 Penicillin 37 Hospital Hypotension
Respiratory
Good Death
Berthier et al (2007)16 Amoxicillin 39 Hospital Hypotension Good Good
Penicillin 38 Hospital Hypotension Good Good
Ceftriaxone 37 Hospital Hypotension Good Neurological damage
Amoxicillin 40 Hospital Hypotension Good Death
Amoxicillin 36 Hospital Hypotension Good Neurological damage
Sengupta et al (2008)3 Cefotaxime ? Term Hospital Hypotension Good Death
Chaudhuri et al (2009)2 Penicillin 40 Hospital Hypotension
Rash
Good Neurological damage
Sleth et al (2009)17 Amoxicillin 38 s Hospital Hypotension
Rash
Good Good
Box 1 Clinical criteria for diagnosing anaphylaxis.19
Anaphylaxis is highly likely when any one of the following three
criteria is fulﬁlled:
1. Acute onset of an illness (minutes to several hours) with
involvement of the skin, mucosal tissue or both (eg,
generalised hives, pruritus or ﬂushing and swollen
lips-tongue-uvula) and at least one of the following:
A. Respiratory compromise (eg, dyspnoea,
wheeze-bronchospasm, stridor, reduced PEF and
hypoxemia)
B. Reduced blood pressure (BP) or associated symptoms of
end-organ dysfunction (eg, hypotonia/collapse, syncope
and incontinence)
2. Two or more of the following that occur rapidly after
exposure to a likely allergen for that patient (minutes to
several hours):
A. Involvement of the skin–mucosal tissue (eg, generalised
hives, itch-ﬂush and swollen lips-tongue-uvula)
B. Respiratory compromise (eg, dyspnoea,
wheeze-bronchospasm, stridor, reduced PEF and
hypoxemia)
C. Reduced BP or associated symptoms (eg, hypotonia/
collapse, syncope and incontinence)
D. Persistent gastrointestinal symptoms (eg, cramping
abdominal pain, vomiting)
3. Reduced BP after exposure to a known allergen for that
patient (minutes to several hours):
A. Infants and children: low systolic BP (age-speciﬁc) or
greater than 30% decrease in systolic BP
B. Adults: systolic BP of less than 90 mm Hg or greater than
30% decrease from that person’s baseline
Adapted from.19 BP, blood pressure; PEF, peak expiratory ﬂow.
Figure 7 Newborn autopsy. Signs of neuronal necrosis at medulla
oblongata—eosinophilic cytoplasm and pycnotic nuclei (arrow).
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place 48 h before delivery. This suggests that central nervous
system injuries were secondary to the described severe episode
of maternal anaphylaxis.
Controversies exist regarding the best timing and mode of
delivery of the neonate following anaphylaxis during pregnancy.
In view of inadequate maternal resuscitation, immediate caesar-
ean delivery may provide a better outcome for the neonate.2
Continuous vigilance, adequate knowledge and a high degree of
suspicion are essential for prompt diagnosis and treatment.
A consensus about the management of anaphylaxis in pregnancy
is highly desirable. It is also advisable that all services develop
and discuss a management protocol of anaphylaxis in pregnant
women. In our case, the stabilisation of the mother in the emer-
gency department with ﬂuids, antihistamines and corticosteroids
drugs, without adrenaline, was probably insufﬁcient to prevent
fetal brain damage and the reported ﬁnal outcome.
Learning points
▸ Anaphylaxis is a rare event in pregnancy.
▸ High degree of suspicion is essential for prompt diagnosis
and treatment.
▸ Permanent damage is observed in the neonates rather than
in mothers.
▸ Continuous vigilance of fetal well-being for 48–72 h after an
episode of maternal anaphylaxis is crucial in order to
identify precocious signs of fetal distress.
▸ The development and implementation of a maternal
anaphylaxis management protocol by a multidisciplinary
team of obstetricians, neonatologists and anaesthesiologists
is highly advisable.
▸ The chemoprophylaxis of SBS infections and treatment of
pregnant infections should give warning for the accurate
identiﬁcation of predisposed women.
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